Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

Kasper, Christoph; Zahner, J; Hg, Sayer

doi:10.1007/s00432-002-0372-z

Cited by 19 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we examined a novel approach of administering EPO and G-CSF concurrently, which has been known to exert synergistic effects in promoting angiogenesis, neurogenesis and functional recovery in experimental stroke models [ 30 , 33 ]. Although combined administration of EPO and G-CSF represents a promising therapeutic strategy for stroke patients, most studies have focused on peripheral efficacy for the treatment of myelodysplastic syndromes [ 34 , 35 , 36 , 37 ]. Based on these previous reports showing the therapeutic advantages of an EPO and G-CSF combination [ 30 , 33 ], we evaluated whether EPO+G-CSF combination therapy safely yielded hematological and functional improvement in stroke patients.…”

Section: Discussionmentioning

confidence: 99%

Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

Shin

Cho

2016

IJMS

View full text Add to dashboard Cite

Erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) are known to have neuroprotective actions. Based on previous reports showing the synergistic effects of EPO+G-CSF combination therapy in experimental models, we investigated the safety of EPO+G-CSF combination therapy in patients with chronic stroke. In a pilot study, 3 patients were treated with EPO and G-CSF for 5 consecutive days, with follow-up on day 30. In an exploratory double-blind study, 6 patients were allocated to treatment with either EPO+G-CSF or placebo. Treatment was applied once a day for 5 days per month over 3 months. Participants were followed up for 6 months. To substantiate safety, vital signs, adverse events, and hematological values were measured on days 0, 5, and 30 in each cycle and on day 180. Functional outcomes were determined on day 0 and 180. In the laboratory measurements, EPO+G-CSF combination therapy significantly elevated erythropoietin, CD34+ hematopoietic stem cells, white blood cells, and neutrophils on day 5 of each cycle. There were no observations of serious adverse events. In the functional outcomes, the grip power of the dominant hand was increased in the EPO+G-CSF treatment group. In conclusion, this exploratory study suggests a novel strategy of EPO+G-CSF combination therapy for stroke patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

Shin

Cho

2016

IJMS

View full text Add to dashboard Cite

show abstract

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Mundle

Lefèbvre

Vekeman

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND: Epoetin α (EPO) continues to be the initial treatment of choice for most anemic patients with myelodysplastic syndromes (MDS). Over the years, different therapeutic strategies have been adopted to optimize the clinical benefits of EPO in this setting. METHODS: In the current meta‐analysis of published literature, erythroid response (ER) rates with EPO as a single agent versus its combination with granulocyte–colony‐stimulating factor (G‐CSF) or granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF) were compared. RESULTS: The assessment indicated that the ER rates were comparable between the 2 EPO‐based therapeutic strategies. Furthermore, EPO monotherapy at a higher dose of 60,000 to 80,000 U weekly produced significantly higher ER rates (64.5%) compared with the standard oncology dose of 30,000 to 40,000 U weekly either as a single agent (49%; P < .001) or in combination with G‐CSF/GM‐CSF (50.6% P = .007). In addition, when transfusion‐dependent patients were assessed separately, both EPO monotherapy and its combination with G‐CSF/GM‐CSF produced comparable and appreciable levels of transfusion independence (28.8% and 24.8%, respectively). CONCLUSIONS: In the current meta‐analysis, higher doses of EPO demonstrated better ER rates compared with EPO at standard doses alone or in combination with G‐CSF/GM‐CSF. Furthermore, the authors concluded that prospective clinical studies are warranted to evaluate the use of higher doses of EPO in anemic patients with MDS. Cancer 2009. © 2009 American Cancer Society.

show abstract

Acute Myeloid Leukemia and the Myelodysplastic Syndromes

Kolitz

Oncology

View full text Add to dashboard Cite

Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

Cited by 19 publications

References 29 publications

Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Acute Myeloid Leukemia and the Myelodysplastic Syndromes

Contact Info

Product

Resources

About